Prothena Corporation plc
PRTAHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeProthena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. The $522.5M market capitalization puts PRTA squarely in small-cap range for its industry. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Market Cap
$522.5M
Beta
-0.23
P/E (TTM)
—
P/E (Fwd)
-7.62
EPS (TTM)
$-2.81
EPS (Fwd)
$-1.31
ROE
-40.3%
ROA
-13.8%
Cash
$329.5M
Total Debt
$7.7M
Free CF
-$31.6M
52W Change
117.4%
Annual Financials
Cash vs Debt
Prothena Corporation plc holds $329.5M in cash against $7.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$31.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -40.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $53.9M to $9.7M.
PRTA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Prothena Corporation plc and its sector.